Hey mate. Before I answer you, I will open with the...

Hey mate.

Before I answer you, I will open with the cardioprotection mechanims as I understand them/it influences ROS production (at the least), which can have far reaching effects in many systems. This is particularly important for cells that do not replicate (like cardiac cells). When ROS cause enough cell damage to push it over a threshold, the cell will permanently die. All Bisantrene has to do is prevent some of the damage done so that the threshold is not met and a good number of non replicating cells survive, and we are good to go for the worlds first CPACS.

This is where I believe Bisantrene's cardioprotective effect is relevant to your point. As a result of the prevention of permanent damage typically associated with chemotherapy, we would expect a reduction in the rates of cardiotoxicity-related events, such as the ones you've mentioned. Though, this effect would primarily apply within the field of oncology.

Regarding heart health beyond oncology, while Bisantrene is extremely well tolerated in comparison to other therapies, I don't think it has the safety profile for application outside of oncology. In all honesty, the drug is wild in how broadly it targets systems, hah. I think you may be right regarding the mechanism of cardioprotection having potential uses other than in combination with anti-cancer therapy, but I don't think Bisantrene as the molecule it is will feature in heart health beyond oncology.